Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Beats Estimates By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH) announced its earnings results on Tuesday. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.25, FiscalAI reports. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million.

Dianthus Therapeutics Trading Up 1.0%

Shares of DNTH stock traded up $0.90 on Tuesday, reaching $90.24. 343,810 shares of the stock were exchanged, compared to its average volume of 552,587. The company has a market capitalization of $4.91 billion, a price-to-earnings ratio of -22.01 and a beta of 1.18. The business’s 50 day moving average price is $79.60 and its 200 day moving average price is $55.57. Dianthus Therapeutics has a twelve month low of $16.64 and a twelve month high of $96.50.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DNTH. Wedbush upped their price objective on Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Robert W. Baird boosted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Wells Fargo & Company started coverage on Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target on the stock. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $63.00 to $123.00 in a research report on Tuesday, March 10th. Finally, Oppenheimer lifted their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $115.55.

Insiders Place Their Bets

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Edward Carr sold 43,682 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The disclosure for this sale is available in the SEC filing. Insiders sold 323,021 shares of company stock valued at $26,564,008 over the last quarter. Corporate insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. raised its stake in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after acquiring an additional 6,323 shares in the last quarter. Invesco Ltd. lifted its position in Dianthus Therapeutics by 31.1% in the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after acquiring an additional 4,962 shares during the last quarter. Alliancebernstein L.P. lifted its position in Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after acquiring an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the second quarter valued at $27,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.